Developer of diagnostic platform technology for cancer detection. The proprietary impedance-based platform technology for the detection of cancers. The company has developed a single impedance parameter that differs markedly between healthy and cancer tissue, called the Cole Relaxation Frequency. The company was founded in 2001 and headquartered in Milwaukee, United States. It has raised $8.8M in series b funding, with backing from Builders VC, Gore Range Capital, ChinaBio Partnering Forum, Dipalo Ventures, and others. The company operates in the Life Sciences - Genomics, Life Sciences - Oncology space. Its offerings span Oncology - In-Vitro Diagnostic Tests - Diversified. The company leverages advanced technology to deliver innovative solutions tailored to its target market, addressing key industry challenges and driving value for its customers.
← All startups
NovaScan
Series BDeveloper of diagnostic platform technology for cancer detection. The proprietary impedance-based platform technology for the detection of cancers. The company has developed a single impedance parameter that differs markedly between healthy and cancer tissue, called the Cole Relaxation Frequency. The company was founded in 2001 and headquartered in Milwaukee, United States. It has raised $8.8M in series b funding,…
About
Business model
Oncology > In-Vitro Diagnostic Tests > Diversified,
Genomics > Applied Genomics > Clinical Genomics > Diagnostics > Sequencing-based > Precision Medicine > Oncology
Institutional investors
Builders VCGore Range CapitalChinaBio Partnering ForumDipalo VenturesHBS Alumni Angels ChicagoStateline AngelsNational Science FoundationAurora Venture CapitalGreen Park & Golf VenturesStanding Oak Venture Partners
Latest coverage
📰 See all funding news — keep up with the raises that set comps.
Investor directory
🗂️ Browse all funds in our directory — active VCs and growth investors by stage and sector.